Cevira

This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages) Parts of this article (those related to clinical trial phase III) need to be updated. Please help update this article to reflect recent events or newly available information. (September 2016) This article may have been created or edited in return for undisclosed payments, a violation of Wikipedia's terms of use. It may require cleanup to comply with Wikipedia's content policies, particularly neutral point of view. See our advice if the article is about you and read our scam warning in case someone asks for money to edit this article. (June 2019) (Learn how and when to remove this message)

Cevira is in development as a local treatment for Cervical intraepithelial neoplasia lesions and human papilloma virus (HPV) of the cervix without damaging healthy tissue. With Cevira, Photocure aims to develop the first non-surgical treatment for precancerous cervical lesions using photodynamic therapy (PDT). Cevira treatment is administered locally and remains in contact with the cervix to deliver treatment for up to 24 hours. A cup holds the ointment against the cervix for initial absorption. After a few hours, a light source within the cup emits light at a specific wavelength so the Active Pharmaceutical Ingredient, hexylaminolevulinate (HAL), reacts with the tissue.

References